UK markets closed

Novo Nordisk A/S (0QIU.L)

YHD - YHD Delayed price. Currency in USD
Add to watchlist
114,191,998,976.00+19.80 (+0.00%)
As of 06:07PM EDT. Market open.
Full screen
Previous closeN/A
YTD returnN/A
Expense ratio (net)N/A
CategoryN/A
Last cap gainN/A
Morningstar ratingN/A
Morningstar risk ratingN/A
Sustainability rating
Net assetsN/A
Beta (5Y monthly)N/A
YieldN/A
5y average returnN/A
Holdings turnoverN/A
Last dividendN/A
Average for categoryN/A
Inception dateN/A
  • Globe Newswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 27 June 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiat

  • Stockopedia

    Will investors benefit from quality and momentum at Novo Nordisk A/S?

    The Novo Nordisk A/S (CPH:NOVO B) share price is currently trading at DKK761.9. But to predict what the price will look like in the next 12 months and beyond, ...

  • Globe Newswire

    Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency

    Investigational phase 3 data for Sogroya® (somapacitan) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress1 Atlanta, Georgia (US), 12 June 2022 – Today, Novo Nordisk announced results of once-weekly Sogroya® (somapacitan) injection in helping children achieve growth targets of annualised height velocity (AHV).1 These phase 3 results from the REAL 4 study, in prepubertal children with growth hormone deficiency (GHD), were presented today at the Endocrin